It is so important to understand how cancer treatments impact cardiovascular health!

TROPION-Breast05: a randomized phase III study of Dato-DXd with or without durvalumab versus chemotherapy plus pembrolizumab in patients with PD-L1-high locally recurrent inoperable or metastatic triple-negative breast cancer - Apr 17, 2025 @journals.sagepub.com journals.sagepub.com/doi/10.1177/...

Cardio-Oncology screening program ensures timely referrals for cardiotoxicity #oncologynursing #ONS50 #ONSCongress www.oncologynurseadvisor.com/reports/canc...

I just had to explain the expression “burning the candle at both ends” to my 9yo. But, yep. #currentsituation

Don't miss this newly published review discussing recent advances in immune checkpoint inhibitors for #TripleNegativeBreastCancer. 🔓 pubmed.ncbi.nlm.nih.gov/40196378/ @ccortimd.bsky.social @stolaney1.bsky.social #TNBC #BreastCancer

In a multivariable analysis, omitting ET was associated w/⬆️ risk of death HR 1.23; For ER 1%-5% HR 1.16; For ER 6%-10% HR 1.42 Endocrine Therapy Omission in ER–Low (1%-10%) Early-Stage Breast Cancer | @oncoalert.bsky.social ascopubs.org/doi/10.1200/...

Congratulations to the University of Rochester for being named the 73rd NCI designated Cancer Center!!!!

Using Epic Signal data for 15.7K oncologists (2019->22): Mean overall EHR inbox messages ⬆️ 19%, mean overall patient-initiated messages ⬆️ 34%, & total InBasket time ⬆️ 25.4%. Total weekly EHR time by subspecialty: med onc>>gyn onc>>surg onc>>rad onc>>ped onc #burnout academic.oup.com/jnci/advance...

On International Women’s Day spending time with this amazing group of women who provide flying fishing retreats for breast cancer survivors!

Important to consider comorbidities when selecting first line therapy in HR+HER2- metastatic breast cancer !

Dear colleagues. We have an exciting opportunity for a breast cancer medical oncologist in Rochester New York! If you are interested in leading a dynamic clinical research program let me know. Come and join a growing team while enjoying the wonderful nature of upper state New York!

Interesting endpoint and trial. Few MBC patients treated and very small. For oligoprogressive cancer, SBRT could delay time to systemic therapy change. This could could valuable for the right patient trying to delay time to chemotherapy. www.redjournal.org/article/S036...

🆕 #HELEN006 trial: weekly nab-paclitaxel with trastuzumab & pertuzumab showed a higher pCR (66.3%) 🆚 docetaxel + carboplatin (57.6%) in HER2-positive #eBC, with fewer severe side effects. A potential new standard for neoadjuvant therapy❓ @oncoalert.bsky.social thelancet.com/journals/lanon…

What is the impact of drug-drug interactions between palbociclib and proton pump inhibitors in #breastcancer? 💊 Can PPI use explain why the PALLAS trial was negative? Now out in @ESMO_Open our analysis of #PALLAS exploring this question👇🏻 @oncoalert.bsky.social www.sciencedirect.com/science/arti...

Happy new year to all

77510762.flowpaper.com/ICOS2024News... Thanks to all of my cardio-oncology colleagues for another successful year! We have made tremendous progress in the treatment of cancer - let’s not forget about cardiovascular health. Looking forward to 2025 - Cute Cancer Save Herts!

3. Insurance profits outpace health care spending

Survivorship means different things to different individuals. One of which remains how to best operationalize the guidance from nationally recognized organizations and clinical practice guidelines to ensure equitable & comprehensive care #oncsky #oncologynursing jnccn.org/view/journal...

📣Abstract deadline for St. Gallen’s Breast Cancer Consensus Conf extended!! The top 5️⃣ posters present in front of global leaders. 🌍 [plus you’ll join me in beautiful Vienna 🇦🇹] Final deadline: Jan 5, 2025 🔗 sgbcc2025.abstractserver.com/submission/#... #oncsky #SGBCC2025 #bcsm @oncoalert.bsky.social

Bravo Kate! Thank you for your leadership and commitment to children everywhere.

Overview of #SABCS24! So many important trials presented. @oncoalert.bsky.social #breastcancer

Prostate Cancer Therapy Cardiotoxicity Map: 💟Cardiotoxicity matters in prostate cancer care. ADT+docetaxel+darolutamide shows less hypertension & arrhythmias vs ADT+docetaxel+abiraterone acetate+prednisone in mHSPC. #ProstateCancer #Oncology @oncoalert.bsky.social @oncbrothers.bsky.social

Congratulations to Elizabeth A. Mittendorf, MD, PhD, MHCM, FASCO, who has been elected 2026-27 @ascopost.bsky.social president. Dr. Mittendorf will be the seventh @danafarber.bsky.social-affiliated physician to serve as president since ASCO was founded in 1964. bit.ly/3VJ5TUQ

www.sciencedirect.com/science/arti... Many new promising cancer drugs in development. Let’s work together to understand the impact of these agents on cardiovascular health!

Y'all...Mike Danso isn't on social media. He said we may be able to convince him to join- give me some likes from #SABCS24!

We are getting on board! @oncoalert.bsky.social

Welcome @ascocancer.bsky.social!

Sharing this Cancer Straight Talk episode from a few months ago as it’s even more relevant after the data and discussions of weight loss drugs and breast cancer at #SABCS24 this week. @sabcs.bsky.social @mskcancercenter.bsky.social omny.fm/shows/cancer...

Big takeaway from 2 sessions Tuesday #SABCS24: “Dose reduction is a normal process” and dose optimization needs to be looked at early in clinical trials. 🗣️advocates Victoria Goldberg and Julia Maues who drove this home & talked abt Patient-Centered Dosing Initiative (therightdose.org) #Cansky #bcsm

ZEST—a ph3 trial for TNBC w/ ctDNA screening 🛑stopped early due to low randomization 🩻 50% with mets at time ctDNA+ ⏲️ ctDNA+ occurred often on 1st test/  ≤6 mos from EoT ▫️Recurrence-free interval longer w/ niraparib, but not powered for endpoint #SABCS24 @oncoalert.bsky.social

Fantastic ER+ #bcsm summary and algorithm by Dr. Danso at year in review. First line CDK 2nd line profile driven ADC/chemo once endo-R! @sabcs.bsky.social #SABCS24 @oncoalert.bsky.social

Wrapping up another fantastic #SABCS! Amazing, practice-changing data were presented. I’ve updated the algorithms and added key studies from the meeting— I finally ran out of space in HR+ disease! #SABCS24 @oncoalert.bsky.social

Sequencing of ADCs a challenge in the real world setting. #sabcs2024

Ian Krop discussant on ctDNA in discussing the ZEST trial: No study has shown that intervening on a positive trst improves outcomes No study has shown that deescalating therapy on a negative test is safe For trial use only! #SABCS24

Dr. Krop emphasizes we don't have the data in #bcsm that the GI literature does for MRD. 🛑 Should NOT order tests (outside of a clinical trial) without clear actions to take based on results ‼️ ❓Will outcomes be changed in ctDNA+? Unsure. #SABCS24 @sabcs.bsky.social @oncoalert.bsky.social

Anthracyclines still have a role in the treatment of those patients with early breast cancer at very high risk of disease recurrence!

Wow! Median PFS was 44.3 months for pts treated with IBRANCE in combination with HP and endocrine therapy, and 29.1 months (95% CI: 23.3-38.6) for patients treated with HP and endocrine therapy alone [HR: 0.74 (95% CI, 0.58-0.94); p= 0.0074]. 44 month first-line PFS! @oncbrothers.bsky.social #SABCS

Omission of Axillary surgery continues to build momentum Here in pts w/ cN0 T1-2 invasive breast cancer—omission is noninferior to SLNB w 6 years med f/u Axillary Surgery in Breast Cancer — Primary Results of the INSEMA Trial www.nejm.org/doi/full/10.... #SABCS24 @oncoalert.bsky.social @nejm.org

Thanks to those who stopped by for our International cardio-oncology society (ICOS) reception during the 2024 SABCS symposium #sabcs2024

ADCs offer so much promise for our patients but still need to understand; sequencing, biomarkers for response , toxicity management and drivers of resistance. #sabcs2024

Practice change ALERT in the POST-CDK4/6 HR+, HER2- space.

LeVee et al; Real world immune mediated toxicity (iTox) in >400 early stage breast cancer pts in multi-institutional study. Nearly 73% incidence of all grade iTox! 2x higher than reported in Keynote 522. Age >50 and CDK risk factors for iTox @oncbrothers.bsky.social #SABCS24

So important to consider CV events in patients with cancer. Great session at SABCS2024 on ICI toxicity!

To all my ASCO colleagues please remember to vote! It is so important to make your voice heard.

Honored to have been named as one of the 100 influential women in oncology by @oncodaily #WomenInMedicine 👩🏻‍⚕️ oncodaily.com/positive/100...

2025 will be the Top 100 OncoInfluencers on @bsky.app oncodaily.com/positive/bre...